Madrigal Pharmaceuticals, Inc.
MDGLNASDAQHealthcare● Active
$486.98
$-5.85(-1.19%)
Market Cap$11.2B
P/E Ratio—
52W High$615
52W Low$271.96
Madrigal Pharmaceuticals, Inc. (MDGL) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · MDGL · as of 2026-06-08
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($0.29B) | ($0.47B) | ($0.37B) | ($0.30B) | ($0.24B) |
| Depreciation & Amort. | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Stock-Based Comp. | $0.10B | $0.08B | $0.05B | $0.03B | $0.03B |
| Change in Working Capital | ($0.01B) | ($0.07B) | ($0.00B) | $0.04B | $0.03B |
| Net Cash from Operations | ($0.19B) | ($0.46B) | ($0.32B) | ($0.22B) | ($0.18B) |
| Investing Activities | |||||
| Capital Expenditure | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) | ($0.00B) |
| Purchases of Investments | ($1.05B) | ($1.13B) | ($0.83B) | ($0.14B) | ($0.39B) |
| Sales of Investments | $1.09B | $0.84B | $0.33B | $0.35B | $0.39B |
| Net Cash from Investing | $0.03B | ($0.27B) | ($0.50B) | $0.21B | ($0.01B) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Dividends Paid | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Debt Issued / Repaid | $0.22B | $0.00B | $0.07B | $0.05B | $0.00B |
| Net Cash from Financing | $0.26B | $0.74B | $0.60B | $0.31B | $0.17B |
| Free Cash Flow | |||||
| Free Cash Flow | ($0.19B) | ($0.46B) | ($0.33B) | ($0.23B) | ($0.18B) |
| FCF Margin %(computed) | -19.83% | -253.72% | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Madrigal Pharmaceuticals, Inc. data
About Madrigal Pharmaceuticals, Inc. (MDGL) Cash Flow Statement
Madrigal Pharmaceuticals, Inc. generated operating cash flow of ($0.19B) and free cash flow of ($0.19B) for 2025 — a FCF margin of -19.83%. Capital expenditure was ($0.00B).
Frequently asked questions
MDGL · 4 questionsMadrigal Pharmaceuticals, Inc. generated free cash flow of ($0.19B) for 2025, up 58.4% year-over-year.
MDGL free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08